Crinetics Pharmaceuticals (CRNX)
(Real Time Quote from BATS)
$53.84 USD
+0.50 (0.94%)
Updated Jul 26, 2024 12:36 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
CRNX 53.84 +0.50(0.94%)
Will CRNX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CRNX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRNX
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
CRNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals
Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
Xencor (XNCR) Reports Q4 Loss, Misses Revenue Estimates
Other News for CRNX
Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Elevance Health (ELV) and Johnson & Johnson (JNJ)
Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Forecasting The Future: 11 Analyst Projections For Crinetics Pharmaceuticals
Optimistic Buy Rating for Crinetics Pharmaceuticals Backed by Promising Drug Developments